var data={"title":"Misoprostol as a single agent for medical termination of pregnancy","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Misoprostol as a single agent for medical termination of pregnancy</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/contributors\" class=\"contributor contributor_credentials\">Monica Dragoman, MD, MPH</a></dd><dd><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/contributors\" class=\"contributor contributor_credentials\">Caitlin Shannon, MPH</a></dd><dd><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/contributors\" class=\"contributor contributor_credentials\">Beverly Winikoff, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/contributors\" class=\"contributor contributor_credentials\">Jody Steinauer, MD, MAS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/contributors\" class=\"contributor contributor_credentials\">Sandy J Falk, MD, FACOG</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jan 03, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Medical methods for induced abortion have emerged over the past two decades as safe, effective, and feasible alternatives to surgery. Nonsurgical alternatives expand a woman's treatment options and, in turn, the quality of care [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/1\" class=\"abstract_t\">1</a>]. Moreover, in some settings, surgical options are not available to women or are not medically feasible.</p><p>In first- and second-trimester abortion, combined treatment with <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> and <a href=\"topic.htm?path=mifepristone-drug-information\" class=\"drug drug_general\">mifepristone</a> is more effective than treatment with misoprostol alone, and thus are considered the gold standard for medical abortion [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/2,3\" class=\"abstract_t\">2,3</a>]. However, misoprostol-alone regimens may be the treatment of choice in settings in which mifepristone is not available or is too costly. In particular, misoprostol is commonly used as a single agent for second trimester induced abortion in the United States and many other parts of the world [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/4,5\" class=\"abstract_t\">4,5</a>].</p><p>This topic review will discuss use of <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> in pregnancy termination. Use of <a href=\"topic.htm?path=mifepristone-drug-information\" class=\"drug drug_general\">mifepristone</a> and other medical and surgical approaches to pregnancy termination and use of misoprostol for fetal demise or labor induction are reviewed separately. (See <a href=\"topic.htm?path=first-trimester-medication-abortion-termination-of-pregnancy\" class=\"medical medical_review\">&quot;First-trimester medication abortion (termination of pregnancy)&quot;</a> and <a href=\"topic.htm?path=overview-of-pregnancy-termination\" class=\"medical medical_review\">&quot;Overview of pregnancy termination&quot;</a> and <a href=\"topic.htm?path=spontaneous-abortion-management\" class=\"medical medical_review\">&quot;Spontaneous abortion: Management&quot;</a> and <a href=\"topic.htm?path=fetal-death-and-stillbirth-incidence-etiology-and-prevention\" class=\"medical medical_review\">&quot;Fetal death and stillbirth: Incidence, etiology, and prevention&quot;</a> and <a href=\"topic.htm?path=techniques-for-ripening-the-unfavorable-cervix-prior-to-induction\" class=\"medical medical_review\">&quot;Techniques for ripening the unfavorable cervix prior to induction&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">PHARMACOKINETICS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">Misoprostol</a> is a synthetic E1 prostaglandin (PGE1) developed and approved originally for the prevention of gastric ulcers. Misoprostol is not approved by the United States Food and Drug Administration for uterine evacuation in pregnant women. However, its off-label use for a variety of obstetric and gynecologic indications is endorsed by the World Health Organization and professional medical associations including the American College of Obstetricians and Gynecologists and the Society for Family Planning [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/6-8\" class=\"abstract_t\">6-8</a>]. </p><p><a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">Misoprostol</a> administration in pregnancy induces cervical softening and dilation and uterine contractions at all gestational ages, thereby facilitating uterine evacuation [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/9\" class=\"abstract_t\">9</a>]. The potency of misoprostol's effect, however, varies with gestational age, as well as with route of administration, dose, dosing interval, and cumulative dose.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Gestational age &ndash; The sensitivity of the uterus to prostaglandins increases with gestational age [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/9\" class=\"abstract_t\">9</a>]. For this reason, providers generally use decreasing amounts of <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> with increasing gestational age.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Route of administration &ndash; <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">Misoprostol</a> can be administered by the following routes: vaginal, oral, sublingual, buccal, or rectal [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/10-15\" class=\"abstract_t\">10-15</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Serum level &ndash; The pharmacokinetic profile varies by route [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/10,11,14,15\" class=\"abstract_t\">10,11,14,15</a>]. Oral or sublingual administration leads to a rapid peak in serum level, which appears to decrease in one to three hours. Conversely, with vaginal or buccal dosing, serum levels peak later and remain elevated longer [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/14,15\" class=\"abstract_t\">14,15</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Uterine activity &ndash; Regular and sustained uterine activity is more likely following vaginal, sublingual, or buccal compared with oral administration [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/15\" class=\"abstract_t\">15</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Moist versus dry tablets &ndash; While moistening <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> tablets with normal saline or acetic acid prior to vaginal administration may result in increased absorption, there does not appear to be an increase in clinical effectiveness [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/16-20\" class=\"abstract_t\">16-20</a>]. </p><p/><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">CONTRAINDICATIONS</span></p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Absolute contraindications</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Suspected or confirmed ectopic pregnancy</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Gestational trophoblastic disease</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>High risk of uterine rupture (ie, second or third trimester inductions in women with more than one prior hysterotomy, a prior classical or T-shaped uterine incision, or extensive transfundal uterine surgery)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Intrauterine device (IUD, must be removed before <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> is administered)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Allergy to prostaglandins</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Contraindications to medical or surgical uterine evacuations (eg, hemodynamically unstable, coagulopathy) (see <a href=\"topic.htm?path=overview-of-pregnancy-termination\" class=\"medical medical_review\">&quot;Overview of pregnancy termination&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Relative contraindications</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Misoprostol-alone regimens should be used with caution in women who are at risk for complications of pregnancy termination (eg, coagulopathy). Precautions specific to <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> are considered here. A full discussion of abortion complications is presented separately. (See <a href=\"topic.htm?path=overview-of-pregnancy-termination#H24\" class=\"medical medical_review\">&quot;Overview of pregnancy termination&quot;, section on 'Complications'</a>.)</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Risk factors for uterine rupture</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>While a rare complication, uterine rupture is a risk of <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> use at any time during pregnancy. This risk is likely higher in women with a uterine scar; however, there are few published reports of this complication (<a href=\"image.htm?imageKey=OBGYN%2F58285\" class=\"graphic graphic_table graphicRef58285 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/21\" class=\"abstract_t\">21</a>]. In a systematic review of available studies, the risk of rupture was 0.3 percent among women with a prior cesarean delivery who were undergoing second trimester misoprostol-induced abortion [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/22\" class=\"abstract_t\">22</a>]. Advanced gestational age, high gravidity (&ge;3 pregnancies) or uterine anomalies may also increase risk of rupture.</p><p>Uterine rupture has only been reported once in women undergoing first-trimester medical abortion [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/23\" class=\"abstract_t\">23</a>].</p><p>In the second trimester, uterine rupture remains a rare complication, but it has been reported more frequently than in the first trimester [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/24-32\" class=\"abstract_t\">24-32</a>]. Case reports of uterine rupture in women undergoing second trimester abortion with <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> include women with scarred [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/24-29\" class=\"abstract_t\">24-29</a>] and unscarred uteri [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/29-32\" class=\"abstract_t\">29-32</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Scarred uterus &ndash; There are no high-quality data regarding the risk of uterine rupture with use of <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> for first or second trimester pregnancy termination. Among five published case series of women with a prior cesarean section who were undergoing second trimester misoprostol abortion (n = 858), two cases of uterine rupture were reported [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/24,25,33-35\" class=\"abstract_t\">24,25,33-35</a>]; however, they were underpowered to detect this rare complication. Further, a systematic review found the overall risk to be low (0.8 percent; n = 512) but significantly higher among those with two or more previous cesareans as compared with those with no previous cesarean (2.5 versus 0.08 percent, relative risk 17.55, 95% CI 3.00-102.8) [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/36\" class=\"abstract_t\">36</a>].</p><p/><p class=\"bulletIndent1\">According to observational data regarding obstetric labor induction, <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> induction is contraindicated in women with more than one hysterotomy, a prior classical or T-shaped uterine incision, or extensive transfundal uterine surgery. It has not been established whether these risks apply equally to patients undergoing first or second trimester induction. (See <a href=\"topic.htm?path=choosing-the-route-of-delivery-after-cesarean-birth#H15065615\" class=\"medical medical_review\">&quot;Choosing the route of delivery after cesarean birth&quot;, section on 'Inappropriate candidates'</a>.)</p><p/><p class=\"bulletIndent1\">We counsel women that a uterine scar is not a contraindication for first trimester <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> induction, but that the risk may increase with increasing gestational age, particularly in the late second trimester. We counsel women about risk and monitor them for signs of rupture.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Unscarred uterus &ndash; In reports of uterine rupture in women without previous uterine surgery, risk factors included grand multiparity [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/29,30\" class=\"abstract_t\">29,30</a>], gestational age greater than 23 weeks [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/28\" class=\"abstract_t\">28</a>], and use of <a href=\"topic.htm?path=oxytocin-drug-information\" class=\"drug drug_general\">oxytocin</a> in addition to <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/29\" class=\"abstract_t\">29</a>]. However, oxytocin can generally be used safely in combination with misoprostol [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/30\" class=\"abstract_t\">30</a>]. For pregnancies at 23 or more weeks, it is controversial whether it is necessary to decrease the misoprostol dose or increase dosing interval, though it may be prudent to do so [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/37,38\" class=\"abstract_t\">37,38</a>].</p><p/><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Breastfeeding</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">Misoprostol</a> is excreted transiently and at low levels in human breast milk [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/39\" class=\"abstract_t\">39</a>]. It appears that the levels rise and decline within three to five hours of administration [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/9,39\" class=\"abstract_t\">9,39</a>]. It is reasonable to counsel women who receive misoprostol while breastfeeding to pump and discard all milk produced within five hours after each dose.</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h1\">PRETREATMENT EVALUATION AND PREPARATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>All women should undergo an initial evaluation, including a medical history and a physical examination confirming gestational age. Ultrasound is necessary only if there is uncertainty about gestational age, pregnancy location or the presence of gestational trophoblastic disease. If an ultrasound is not performed, the pregnancy should be confirmed with a urine or serum human chorionic gonadotropin (hCG). Blood type and antibody status are checked and Rh <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information\" class=\"drug drug_general\">immune globulin</a> given if indicated. If a patient has an IUD, it must be removed.</p><p>One of the advantages of <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> induction is that it can be performed safely and effectively without mechanical dilation (eg, rigid or osmotic dilators). Further, there is no evidence that pretreatment with laminaria for inductions after 15 weeks offers any clinical benefit. Two randomized trials in women undergoing second trimester termination reported that use of laminaria compared with no mechanical dilation did not reduce (16 and 17 hours) [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/40\" class=\"abstract_t\">40</a>] and may actually prolong (14 versus 11 hours) [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/41\" class=\"abstract_t\">41</a>] induction time; one trial found an increase in the use of <a href=\"topic.htm?path=morphine-drug-information\" class=\"drug drug_general\">morphine</a> in patients treated with laminaria [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/41\" class=\"abstract_t\">41</a>]. A full discussion of cervical preparation for pregnancy termination can be found separately. (See <a href=\"topic.htm?path=overview-of-pregnancy-termination#H9\" class=\"medical medical_review\">&quot;Overview of pregnancy termination&quot;, section on 'Cervical preparation'</a>.)</p><p>There is no high quality evidence regarding the use of antibiotic prophylaxis for medical abortion (ie, no invasive methods for cervical preparation or uterine evacuation). However, following several deaths due to clostridial sepsis in the United States in patients who received vaginal <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> in combination with <a href=\"topic.htm?path=mifepristone-drug-information\" class=\"drug drug_general\">mifepristone</a>, some organizations, such as Planned Parenthood (the largest abortion provider in the United States), have introduced the use of prophylactic antibiotics [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/42,43\" class=\"abstract_t\">42,43</a>]. However, deaths due to clostridial infection have been reported among women administering misoprostol both vaginally and buccally [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/44\" class=\"abstract_t\">44</a>]. Further, a study showed that the prevalence of rectal and vaginal clostridial presence is both relatively rare and transient [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/45\" class=\"abstract_t\">45</a>]. (See <a href=\"topic.htm?path=first-trimester-medication-abortion-termination-of-pregnancy#H16672499\" class=\"medical medical_review\">&quot;First-trimester medication abortion (termination of pregnancy)&quot;, section on 'Prophylactic antibiotics'</a>.)</p><p>Pretreatment evaluation for pregnancy termination is discussed in detail separately. (See <a href=\"topic.htm?path=overview-of-pregnancy-termination#H3\" class=\"medical medical_review\">&quot;Overview of pregnancy termination&quot;, section on 'Preoperative considerations'</a> and <a href=\"topic.htm?path=prevention-of-rhesus-d-alloimmunization-in-pregnancy\" class=\"medical medical_review\">&quot;Prevention of Rhesus (D) alloimmunization in pregnancy&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h1\">DATA ON DRUG ADMINISTRATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The optimal <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> regimen at any gestational age is determined by achieving a balance among effectiveness, adverse effects, and acceptability to patients. As an example, higher doses and shorter dosing intervals increase effectiveness, but also may result in higher rates of adverse effects and complications [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/9\" class=\"abstract_t\">9</a>].</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Route of administration</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Effectiveness (defined as complete abortion without surgical intervention) is higher with vaginal compared with oral administration in both first and second trimesters [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/46-49\" class=\"abstract_t\">46-49</a>]. However, in a randomized trial, women preferred oral rather than vaginal dosing [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/13\" class=\"abstract_t\">13</a>]. </p><p>Accumulating evidence regarding sublingual administration appears promising regarding effectiveness and patient acceptability [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/50-52\" class=\"abstract_t\">50-52</a>]. Buccal <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> is also used frequently in combination with <a href=\"topic.htm?path=mifepristone-drug-information\" class=\"drug drug_general\">mifepristone</a>. As a single agent, two studies have found that buccal misoprostol can be effective for first trimester induction and may be effective in second trimester abortion [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/53,54\" class=\"abstract_t\">53,54</a>]. Its use has not been compared to either vaginal administration or sublingual administration, which are preferable [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/53,54\" class=\"abstract_t\">53,54</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Oral versus vaginal dosing &ndash; At eight or fewer weeks of gestation, a comparative study evaluated three oral and four vaginal regimens in 260 women and showed that the rate of complete abortion is higher with vaginal compared with oral administration (43 to 80 versus 39 to 50 percent) [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/46\" class=\"abstract_t\">46</a>].</p><p/><p class=\"bulletIndent1\">For pregnancies between 9 and 12 weeks, there are no high quality data comparing vaginal with oral administration. However, observational studies of vaginal <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> use have reported consistently high rates of complete abortion (85 to 90 percent) [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/55-64\" class=\"abstract_t\">55-64</a>].</p><p/><p class=\"bulletIndent1\">At 13 or more weeks, randomized trials comparing vaginal with oral dosing found that the vaginal route was more effective (86 to 100 versus 45 to 89 percent) and had a shorter induction-to-delivery interval (10 to 15 hours versus 12 to 35 hours) [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/5,48,49,65\" class=\"abstract_t\">5,48,49,65</a>]. Adverse effects were similar between the two routes, with the possible exception of a higher incidence of fever with vaginal dosing [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/48\" class=\"abstract_t\">48</a>], and of nausea and diarrhea with oral dosing [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/65\" class=\"abstract_t\">65</a>]. Findings on adverse effects are not consistent and thus do not provide high quality evidence for guiding route of administration.</p><p/><p class=\"bulletIndent1\">At 24 to 28 weeks, one randomized trial of women with a fetal demise compared oral and vaginal regimens and found a slightly longer time to expulsion in women receiving oral <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/66\" class=\"abstract_t\">66</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Sublingual versus vaginal dosing &ndash; In pregnancies at 12 weeks of gestation or less, data suggest that the sublingual route may be as effective as the vaginal route when dosed appropriately [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/46,50,67\" class=\"abstract_t\">46,50,67</a>]. In a randomized trial that compared two vaginal and two sublingual regimens in 2000 women, vaginal <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> administered every 3 or 12 hours and sublingual misoprostol every three hours were similarly effective (83 to 85 percent), but sublingual misoprostol every 12 hours was less effective (78 percent) [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/67\" class=\"abstract_t\">67</a>]. Women preferred sublingual to vaginal administration. Side effects tended to be more common among women taking misoprostol at 3-hour compared to 12-hour intervals, vaginal or sublingual; and this finding was significant for incidence of fever. Diarrhea and chills were slightly more common in women taking misoprostol sublingually compared to vaginally, but this difference was not statistically significant and, regardless, may not be clinically relevant.</p><p/><p class=\"bulletIndent1\">Similarly, the sublingual route may be as effective as the vaginal route for termination after 12 weeks [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/52,65,68-72\" class=\"abstract_t\">52,65,68-72</a>]. One meta-analysis demonstrated that efficacy at 24 hours was similar (pooled RR 1.04, 95% CI 0.93-1.7), but that vaginal <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> may be more successful at 48 hours (pooled RR 0.96; 95% CI 0.93-0.99) and may shorten the induction-to-abortion interval (WMD -4.54, 95% CI -8.03 to -1.05) [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/71\" class=\"abstract_t\">71</a>]. A second meta-analysis of 40 randomized trials examining medical methods of uterine evacuation for women 12 to 28 weeks pregnant found that while misoprostol was more frequently vaginally administered, sublingual administration was equally effective [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/72\" class=\"abstract_t\">72</a>]. Rates of adverse effects are similar between the two types of dosing; however, patients prefer the sublingual route [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/52,68,69\" class=\"abstract_t\">52,68,69</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Buccal versus oral or vaginal dosing &ndash; Buccal administration of <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> as a single agent for medical termination of pregnancy in the first trimester appears promising [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/73,74\" class=\"abstract_t\">73,74</a>]. Randomized trial data for administration of misoprostol in combination with <a href=\"topic.htm?path=mifepristone-drug-information\" class=\"drug drug_general\">mifepristone</a> for pregnancy up to eight to nine weeks of gestation have found that the efficacy of buccal dosing is similar to vaginal and better than oral dosing [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/75,76\" class=\"abstract_t\">75,76</a>]. Buccal administration was associated with a slight increase in nausea over either oral or vaginal dosing. Patient satisfaction was high across all routes. Used as a single agent, buccal misoprostol was found to have an efficacy of 76 percent among women less than 9 weeks pregnant (n = 147) [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/53\" class=\"abstract_t\">53</a>].</p><p/><p class=\"bulletIndent1\">Studies regarding buccal dosing in the second trimester have also yielded favorable results, but there are no studies regarding use of buccal <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> as a single agent for second trimester pregnancy termination [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/77,78\" class=\"abstract_t\">77,78</a>]. In one randomized trial, the initial misoprostol dose was administered vaginally, and subsequent doses were given either buccally or vaginally [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/79\" class=\"abstract_t\">79</a>]. The median time to abortion in the buccal group did not differ significantly in the buccal compared with vaginal dosing groups (15 versus 12 hours); no difference was found in patient preference for route of administration.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Combined-route regimens for second trimester terminations &ndash; Regimens that combine an initial vaginal <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> dose followed by oral doses have been commonly used for terminations after 12 weeks and appear to be as effective as vaginal-only regimens [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/41,49,80-82\" class=\"abstract_t\">41,49,80-82</a>]. The rationale is to maximize effectiveness and acceptability, while minimizing induction-to-delivery interval, adverse effects and complications. In a randomized trial of 43 women at 13 to 23 weeks of gestation, an initial 800 mcg vaginal misoprostol dose was followed every eight hours by 400 mcg given either orally or vaginally; effectiveness (82 and 87 percent) and induction-to-delivery interval (16 and 21 hours) were similar between the oral and vaginal groups [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/82\" class=\"abstract_t\">82</a>]. A randomized trial demonstrated that 200 mcg buccal doses repeated at six-hour intervals, following an initial 400 mcg vaginal dose, result in a similar induction-to-delivery interval (15 versus 12 hours, respectively) [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/79\" class=\"abstract_t\">79</a>].</p><p/><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Dose and dosing interval</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The optimal regimen is a dose and dosing interval balance which generate sufficient and sustained uterine activity while minimizing adverse effects [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/83\" class=\"abstract_t\">83</a>]. Longer dosing intervals have the benefit of exposing a woman to a decreased risk of adverse effects. Conversely, shorter dosing intervals (closer to three hours) may be necessary to generate sufficient uterine activity, in particular if <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> is given via a route with a rapid rise and fall in serum levels (ie, oral and sublingual) [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/11\" class=\"abstract_t\">11</a>]. Uterine hyperstimulation is rare; however, the risk may increase with shorter dosing intervals.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>9 or less weeks &ndash; Vaginal administration of <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> appears to be more effective at 800 mcg (generally 80 to 90 percent) than 200 or 400 mcg (23 to 46 percent), according to observational data [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/57\" class=\"abstract_t\">57</a>].</p><p/><p class=\"bulletIndent1\">A vaginal dosing interval of 3 to 24 hours (800 mcg PV; total of three to five doses) is typically used to terminate pregnancies up to nine weeks, with reported success rates of 85 to 93 percent in non-comparative studies [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/83\" class=\"abstract_t\">83</a>].</p><p/><p class=\"bulletIndent1\">There are no high quality data comparing different doses of sublingual <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> for terminations at &le;12 weeks. In studies of sublingual-dosing alone and comparative trials with vaginal dosing, 400 to 800 mcg SL is typically used [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/46,50,67\" class=\"abstract_t\">46,50,67</a>]. As noted above, 3- rather than 12-hour dosing interval was found to be significantly more effective in a randomized trial (84 versus 78 percent) [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/67\" class=\"abstract_t\">67</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>10 to 12 weeks &ndash; Lower success rates for misoprostol-alone have been reported for pregnancies at 10 to 12 weeks of gestation (84 to 87 percent) in a few descriptive studies [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/57,62,63,84,85\" class=\"abstract_t\">57,62,63,84,85</a>]. The most effective regimen appears to be 800 mcg PV every 12 to 24 hours for a maximum of three doses [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/62,63\" class=\"abstract_t\">62,63</a>].</p><p/><p class=\"bulletIndent1\">Data from a case series of 50 women suggest that sublingual administration is also effective; the regimen used was 600 mcg SL every three hours up to five doses [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/50\" class=\"abstract_t\">50</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>13 to 22 weeks &ndash; Two <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> regimens, 400 mcg PV every three hours OR 600 PV mcg every 12 hours were safe, effective, and resulted in low induction-to-delivery interval in randomized trials [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/86-88\" class=\"abstract_t\">86-88</a>]. However, these two regimens have not been compared to each other.</p><p/><p class=\"bulletIndent1\">As noted above, it is unclear whether sublingual administration is more or less effective than vaginal in this gestational age range. More research is needed to determine whether sublingual administration should be used among women with gestations 13 to 22 weeks, and the appropriate regimen. (See <a href=\"#H10\" class=\"local\">'Route of administration'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>23 to 28 weeks &ndash; Many studies have examined the use of misoprostol-alone regimens beyond 23 weeks of gestation, and data show that the method, employing a variety of regimens, can be safely and effectively used in women with advanced gestations [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/49,80,87-92\" class=\"abstract_t\">49,80,87-92</a>]. In general, however, termination after 23 weeks is not common in the United States, and an optimal regimen has not been established. When pregnancy termination is performed at &ge;24 weeks, the indication is generally a fetal anomaly.</p><p/><p class=\"bulletIndent1\">The Society for Family Planning (SFP) has published a systematic review and guidelines for pregnancy termination from 24 to 28 weeks; these include data and recommendations for pregnancy termination and labor induction for fetal demise [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/93\" class=\"abstract_t\">93</a>]. For misoprostol-only regimens, 11 studies (7 were randomized trials) were included, and showed that a dosing regimen of <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> PV 100 mcg or 200 mcg given every 4 hours was associated with a 24-hour expulsion rate of 84 to 100 percent, with mean or median expulsion times of 10 to 14 hours. Longer dosing intervals were associated with a longer time to expulsion. Use of a higher dose (400 mcg) was not associated with an increase in efficacy. In addition, a subsequent randomized trial of women with a fetal demise found that a 200 mcg dose was significantly more effective than a 100 mcg dose (76.7 versus 89.5 percent completion at 48 hours) [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/94\" class=\"abstract_t\">94</a>].</p><p/><p class=\"bulletIndent1\">As noted above, uterine sensitivity to prostaglandins and risk of uterine rupture increase with gestational age. Therefore, it may be prudent to use a decreased dose or increased dosing interval in this gestational age range [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/95\" class=\"abstract_t\">95</a>] (see <a href=\"#H2\" class=\"local\">'Pharmacokinetics'</a> above). Uterine rupture is rare, however. There were no uterine ruptures reported among the 700 cases included in the SFP review [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/93\" class=\"abstract_t\">93</a>].</p><p/><p class=\"bulletIndent1\">A retrospective review of second trimester terminations among women with prior cesarean section found that, among the 279 women undergoing termination, there were 3 cases of rupture [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/96\" class=\"abstract_t\">96</a>]. All three cases of rupture were among women with two or more prior cesarean sections. The type of prior incision, termination regimen used, and the length of induction were not specified. In another study, no significant increased risk of uterine rupture was found in women with a prior uterine scar compared to those with no uterine scar <span class=\"nowrap\">(1/44</span> versus <span class=\"nowrap\">2/457)</span> in a population of 518 women undergoing second trimester medical termination with a combination of methods, including <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> alone [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/97\" class=\"abstract_t\">97</a>].</p><p/><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Number of doses</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In pregnancies at 12 or less weeks, it appears that there is little increase in effectiveness after the second dose of <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/64,98\" class=\"abstract_t\">64,98</a>], although most studies have evaluated regimens of three to five doses [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/83\" class=\"abstract_t\">83</a>]. As an example, in one study, effectiveness after a second or third dose were similar (86 and 88 percent) [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/98\" class=\"abstract_t\">98</a>].</p><p>Data on second trimester medical terminations with <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> show that multiple doses are highly effective compared to single doses. As noted above, recommended doses are lower than doses used for first trimester terminations since the uterine is more sensitive to misoprostol and the risk of rupture appears greater [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/6,71,72\" class=\"abstract_t\">6,71,72</a>]. As an example, 25 to 50 mcg doses are generally used for labor induction in the third trimester. The need for repeat doses should be evaluated prior to administration and based on lack of relevant clinical signs of progression (eg, insufficient uterine activity or cervical dilation).</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h1\">CLINICAL REGIMEN</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The regimens listed below are consistent with the regimens proposed by a meeting convened by the World Health Organization (WHO) as a prelude to WHO guidelines (<a href=\"image.htm?imageKey=OBGYN%2F60845\" class=\"graphic graphic_table graphicRef60845 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/83,95,99\" class=\"abstract_t\">83,95,99</a>]. All gestational ages refer to weeks of amenorrhea.</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">9 or less weeks</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">Misoprostol</a> may be administered either in a clinic or at home.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>800 mcg SL every three hours for up to three doses [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/67\" class=\"abstract_t\">67</a>] OR</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>800 mcg PV every 3 to 12 hours for up to three doses [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/46,67\" class=\"abstract_t\">46,67</a>] OR</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>800 mcg buccally every two to three hours</p><p/><p class=\"headingAnchor\" id=\"H15\"><span class=\"h2\">10 to 12 weeks</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We suggest administration in a clinic only due to increased risk of excessive bleeding and possibly of uterine rupture [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/83\" class=\"abstract_t\">83</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>800 mcg PV every 3 to 12 hours for up to three doses [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/62,63\" class=\"abstract_t\">62,63</a>]</p><p/><p class=\"headingAnchor\" id=\"H16\"><span class=\"h2\">13 to 22 weeks</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment should be administered only in a clinic setting with immediate access to emergency surgery and blood transfusion. If delivery has not occurred at 24 hours, the protocol may be repeated [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/86,87\" class=\"abstract_t\">86,87</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>400 mcg PV every three to four hours (max five doses) [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/86\" class=\"abstract_t\">86</a>] OR</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>600 mcg PV every 12 hours [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/87\" class=\"abstract_t\">87</a>]</p><p/><p class=\"headingAnchor\" id=\"H17\"><span class=\"h2\">23 or more weeks</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment should be administered only in a clinic setting with immediate access to emergency surgery and blood transfusion. As noted above, there is no well-established regimen for this gestational age range.&nbsp;The Society for Family planning has published the following regimen [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/93\" class=\"abstract_t\">93</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>100 to 200 mcg vaginal or buccal <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> every 4 to 6 hours for 24 hours</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pretreatment with <a href=\"topic.htm?path=mifepristone-drug-information\" class=\"drug drug_general\">mifepristone</a> &ndash; Mifepristone (200 mg) should be administered 24 to 48 hours prior to the administration of <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a>, where available (see <a href=\"topic.htm?path=second-trimester-pregnancy-termination-induction-medication-termination\" class=\"medical medical_review\">&quot;Second-trimester pregnancy termination: Induction (medication) termination&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H18\"><span class=\"h1\">MONITORING DURING TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Women are monitored during treatment whether it occurs at home or in a clinic setting. The goals of monitoring are to assess treatment efficacy and assess for complications.</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h2\">At-home treatment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A woman undergoing medical termination at home should have easy access to a clinician who can answer questions and manage complications medically or surgically. Patient education should include a description of what she is most likely to experience, how to recognize potential complications (eg, fever, abdominal pain, or prolonged or excessive bleeding), and how and where to seek help, if needed (<a href=\"image.htm?imageKey=OBGYN%2F60845\" class=\"graphic graphic_table graphicRef60845 \">table 2</a>).</p><p>Importantly, a woman should also know to call her provider if it does not seem that the treatment has been effective. Typically, if 48 hours have passed since completion of treatment and a woman has not had bleeding greater than a menstrual period, it is likely that she may have an incomplete abortion or continuing pregnancy [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/100\" class=\"abstract_t\">100</a>].</p><p class=\"headingAnchor\" id=\"H20\"><span class=\"h2\">Facility-based treatment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Examination of presumed products of conception or pelvic examination are performed before each additional <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> dose is administered in order to determine whether the abortion is complete. The frequency and strength of uterine contractions are also monitored, and additional doses should be deferred if uterine contractions are strong (strong to palpation or by patient report) <span class=\"nowrap\">and/or</span> too frequent (&gt;3 <span class=\"nowrap\">contractions/10</span> min) [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/95\" class=\"abstract_t\">95</a>].</p><p>In pregnancies at 13 weeks or greater, if a woman does not abort after 24 hours, the option of a second course of <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> treatment or surgical evacuation can be offered [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/86,88\" class=\"abstract_t\">86,88</a>]. There are insufficient data on the safety and effectiveness of augmentation with other uterotonics (eg, prostaglandins or <a href=\"topic.htm?path=oxytocin-drug-information\" class=\"drug drug_general\">oxytocin</a>) [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/95\" class=\"abstract_t\">95</a>]. As with misoprostol, if additional uterotonics are used, precautions should be taken to avoid uterine hyperstimulation, as it may lead to rupture.</p><p>Expulsion of the placenta should be confirmed. Expulsion usually occurs shortly after the fetus is delivered. After expulsion, the placenta should be examined to see whether it is complete.</p><p>Advice regarding time interval to wait for placental expulsion varies from 30 minutes to four hours; in a retrospective study, there was no morbidity associated with a waiting period of four hours [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/101\" class=\"abstract_t\">101</a>]. If two or more hours have passed and the placenta has not delivered, an infusion of <a href=\"topic.htm?path=oxytocin-drug-information\" class=\"drug drug_general\">oxytocin</a> 10 units in 500 mL of normal saline administered intravenously at a rate of 20 to 30 drops per minute may be given [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/95\" class=\"abstract_t\">95</a>]. If the placenta has not delivered after infusion of oxytocin or the woman starts bleeding excessively, manual or surgical removal of the placenta may be required.</p><p>Before discharge from the clinic, clinicians should observe to monitor vital signs and observe for severe abdominal pain or excessive vaginal bleeding. She can be discharged when she is feeling well and ready to leave <span class=\"nowrap\">and/or</span> when her vital signs are stable.</p><p>If 48 hours have passed and abortion is not complete, surgical evacuation is typically performed [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/95\" class=\"abstract_t\">95</a>].</p><p class=\"headingAnchor\" id=\"H22\"><span class=\"h1\">FOLLOW-UP</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>After treatment, women should be educated about how to recognize complications (eg, fever, abdominal pain, or prolonged or excessive bleeding) (<a href=\"image.htm?imageKey=OBGYN%2F60845\" class=\"graphic graphic_table graphicRef60845 \">table 2</a>). A follow-up visit is conducted at one to two weeks post-treatment. A thorough clinical history and bimanual pelvic examination is performed to evaluate uterine size, bleeding, and assess for infection.</p><p>The most important questions to ask at the follow-up visit are:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Do you feel pregnant?</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Did you see the expulsion of the products of conception?</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>How much bleeding did you have?</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Are you still bleeding?</p><p/><p>These questions and a pelvic examination to determine uterine size are sufficient to detect most women in need of further treatment for incomplete abortion (retained products of conception, no or inconsistent uterine growth, and lack of cardiac activity on ultrasound) or ongoing pregnancy (uterine growth consistent with the time elapsed between the first and follow-up visits and cardiac activity on vaginal ultrasound).</p><p>If there is uncertainty about whether there is an incomplete abortion (retained products of conception, no or inconsistent uterine growth, and lack of cardiac activity on ultrasound) or ongoing pregnancy (uterine growth consistent with the time elapsed between the first and follow-up visits and cardiac activity on vaginal ultrasound), a vaginal ultrasound examination may be necessary. Generally speaking, a serum hCG is only used when there is concern about non-uterine pregnancy <span class=\"nowrap\">and/or</span> when ultrasound is not available.</p><p>While hCG concentration may remain elevated for weeks after complete abortion, a measurement that falls to less than 20 percent of its pre-procedure value generally indicates successful pregnancy termination [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/102\" class=\"abstract_t\">102</a>]. Also, there is no consensus regarding the upper limit of endometrial thickness associated with a successful medical abortion; therefore, it is not a good diagnostic tool for determining whether further intervention may be required [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/103-107\" class=\"abstract_t\">103-107</a>]. (See <a href=\"topic.htm?path=first-trimester-medication-abortion-termination-of-pregnancy#H711260\" class=\"medical medical_review\">&quot;First-trimester medication abortion (termination of pregnancy)&quot;, section on 'Follow-up'</a>.)</p><p>Where available, women could be given a semi-quantitative pregnancy test to take at home one to two weeks after the procedure and asked to call the clinic if the test is still positive [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/108,109\" class=\"abstract_t\">108,109</a>].</p><p>Contraceptive method can be started as soon as possible. (See <a href=\"topic.htm?path=overview-of-pregnancy-termination#H35\" class=\"medical medical_review\">&quot;Overview of pregnancy termination&quot;, section on 'Contraception'</a>.)</p><p class=\"headingAnchor\" id=\"H23\"><span class=\"h1\">OUTCOME</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In early pregnancy, some studies suggest that pregnancy termination efficacy may be higher among women at six weeks and less [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/110,111\" class=\"abstract_t\">110,111</a>] compared with those at six to eight weeks [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/110,111\" class=\"abstract_t\">110,111</a>]. This trend toward higher effectiveness with decreasing gestational age is similar to the results seen in large trials of combined <a href=\"topic.htm?path=mifepristone-and-misoprostol-united-states-not-available-drug-information\" class=\"drug drug_general\">mifepristone-misoprostol</a>.</p><p>Effectiveness (defined as complete abortion) of <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> alone for pregnancy termination is as follows.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>&le;9 weeks (weeks of amenorrhea): 75 to 85 percent [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/67,83\" class=\"abstract_t\">67,83</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>10 to 12 weeks: 80 to 85 percent [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/83\" class=\"abstract_t\">83</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>&ge;13 weeks: 80 to 90 percent [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/95\" class=\"abstract_t\">95</a>]</p><p/><p class=\"headingAnchor\" id=\"H24\"><span class=\"h1\">ADVERSE EFFECTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">Misoprostol</a> is a safe and well-tolerated medication [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/112\" class=\"abstract_t\">112</a>]. Gastrointestinal symptoms (nausea, diarrhea) and fever are the most common adverse effects of misoprostol. These are generally transient and self-limiting.</p><p class=\"headingAnchor\" id=\"H25\"><span class=\"h2\">Gastrointestinal symptoms</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Diarrhea is the major adverse reaction that has been reported consistently, but it is usually mild and self-limiting. Nausea and vomiting may also occur [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/112\" class=\"abstract_t\">112</a>]. The majority of cases can be managed expectantly or with anti-emetic or <span class=\"nowrap\">anti-/diarrheal</span> medication.</p><p>These symptoms have been observed with all four routes of administration; severity may be dose and interval dependent (ie, higher doses and shorter dosing intervals may lead to increased symptoms) [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/67,83,110\" class=\"abstract_t\">67,83,110</a>].</p><p class=\"headingAnchor\" id=\"H26\"><span class=\"h2\">Fever</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Fever, even in the absence of infection is a common effect of <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a>, reported in 5 to 88 percent of patients undergoing first trimester abortion [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/9,57,83\" class=\"abstract_t\">9,57,83</a>]. There is one case report of severe hyperthermia (41.9 <span class=\"nowrap\">C/107</span>.4 F) in a woman who received misoprostol for postpartum hemorrhage prophylaxis [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/113\" class=\"abstract_t\">113</a>]. Fever associated with misoprostol should subside within 24 hours, and antipyretics may be given as needed. If fever persists beyond 24 hours, a women should be evaluated for infection.</p><p>Concern has emerged in North America following the reports of six cases of Clostridia-associated fatal toxic shock syndrome following use of <a href=\"topic.htm?path=mifepristone-drug-information\" class=\"drug drug_general\">mifepristone</a> and <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> for early pregnancy termination (five cases associated with sordellii and one with perfringens) [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/114-117\" class=\"abstract_t\">114-117</a>]. An additional case (of perfringens) was recently reported in a woman who used laminaria and misoprostol for second trimester termination. Although several hypotheses on the mechanism of infection have been put forth, no consensus has been reached [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/118-120\" class=\"abstract_t\">118-120</a>]. (See <a href=\"topic.htm?path=first-trimester-medication-abortion-termination-of-pregnancy#H18\" class=\"medical medical_review\">&quot;First-trimester medication abortion (termination of pregnancy)&quot;, section on 'Fever and infection'</a>.)</p><p class=\"headingAnchor\" id=\"H27\"><span class=\"h2\">Prevention of adverse effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pretreatment with antipyretic and antidiarrheal medications may slightly reduce the severity of gastrointestinal adverse effects [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/121\" class=\"abstract_t\">121</a>]. In a randomized trial of women undergoing pregnancy termination at &le;7 weeks, pretreatment with <a href=\"topic.htm?path=loperamide-drug-information\" class=\"drug drug_general\">loperamide</a> 4 mg and <a href=\"topic.htm?path=acetaminophen-paracetamol-drug-information\" class=\"drug drug_general\">acetaminophen</a> 500 mg prior to <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> 800 mcg pv compared to no pretreatment led to a significant reduction in incidence of diarrhea (23 versus 44 percent), but no difference in vomiting or <span class=\"nowrap\">fever/chills</span>.</p><p class=\"headingAnchor\" id=\"H28\"><span class=\"h1\">COMPLICATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Complications specific to misoprostol-only pregnancy termination are discussed below. As with any uterine evacuation procedure, bleeding or infection may occur. (See <a href=\"topic.htm?path=overview-of-pregnancy-termination#H24\" class=\"medical medical_review\">&quot;Overview of pregnancy termination&quot;, section on 'Complications'</a>.)</p><p class=\"headingAnchor\" id=\"H29\"><span class=\"h2\">Incomplete abortion</span></p><p class=\"headingAnchor\" id=\"H30\"><span class=\"h3\">First trimester</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For women undergoing first-trimester medical abortion, management of ongoing pregnancy (cardiac activity on ultrasound) or incomplete abortion (sac or other evidence of products of conception, but no gestational growth and no cardiac activity on ultrasound) are generally different. We assess women at the follow-up visit (one to two weeks) and advise surgery for all ongoing pregnancies. For incomplete abortion, we advise expectant management or an additional dose of <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a>. For women who receive an additional dose, we schedule a second follow-up assessment at one to two weeks.</p><p>We generally don't give more than one additional dose. This is because the cumulative benefit of additional doses is not established and requiring multiple follow-up visits increases the chance of loss-to-follow-up.</p><p class=\"headingAnchor\" id=\"H31\"><span class=\"h3\">Second trimester</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For women in the second trimester, management of retained products of conception (POCs) depends on the point in the process at which they are suspected or diagnosed.</p><p>After fetal expulsion and before discharge from the hospital or clinic, clinicians should confirm that the fetus and placenta have been completely expelled.</p><p>Many clinicians manage incomplete abortion in the second trimester with surgical evacuation. Clinicians can choose either electric suction curettage or manual vacuum aspiration with appropriately sized cannula (up to 16 mm), depending on the clinical situation, to evacuate retained tissue; sharp curettage is rarely indicated. (See <a href=\"topic.htm?path=first-trimester-pregnancy-termination-uterine-aspiration\" class=\"medical medical_review\">&quot;First-trimester pregnancy termination: Uterine aspiration&quot;</a> and <a href=\"topic.htm?path=overview-of-second-trimester-pregnancy-termination\" class=\"medical medical_review\">&quot;Overview of second-trimester pregnancy termination&quot;</a>.)</p><p>However, some clinicians treat incomplete abortion following a second-trimester induction with an additional dose or two of <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a>. The efficacy of this practice has not been established in the literature, but avoiding surgical intervention may be preferable to some women, and there are no known dangers of giving additional misoprostol doses after fetal expulsion.</p><p>It is rare for retained POCs to be detected only after discharge from the clinic, and there is no standard approach. Management (expectant management, additional <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a>, or surgery) should be tailored to the patient's preferences and the clinical situation.</p><p class=\"headingAnchor\" id=\"H32\"><span class=\"h2\">Uterine rupture</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">Misoprostol</a>, and other agents which stimulate uterine contractions (eg, <a href=\"topic.htm?path=oxytocin-drug-information\" class=\"drug drug_general\">oxytocin</a>, other prostaglandins), may increase risk of dehiscence of a prior uterine scar or uterine rupture. (See <a href=\"#H6\" class=\"local\">'Risk factors for uterine rupture'</a> above.)</p><p>Preprocedure screening of patients for risk factors and close observation during treatment are crucial to prevent or detect early signs of uterine rupture. In addition, the minimum cumulative <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> dose should be used (ie, lowest dose, longest dosing interval, lowest number or total doses).</p><p>Clinical manifestations of uterine rupture following medical termination of pregnancy are variable. In women with known uterine scarring, uterine rupture should always be strongly considered if severe and persistent abdominal pain <span class=\"nowrap\">and/or</span> signs of intraabdominal hemorrhage are present. Vaginal bleeding is not a cardinal symptom, as it may be modest, despite major intraabdominal hemorrhage. Other clinical manifestations include hypotension ranging from subtle to severe (hypovolemic shock), cessation of uterine contractions, and uterine tenderness. Hematuria may occur if the rupture extends to the bladder. In a stable patient, ultrasound examination may confirm the diagnosis [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/26,122\" class=\"abstract_t\">26,122</a>]. (See <a href=\"topic.htm?path=choosing-the-route-of-delivery-after-cesarean-birth#H15065615\" class=\"medical medical_review\">&quot;Choosing the route of delivery after cesarean birth&quot;, section on 'Inappropriate candidates'</a>.)</p><p>Rupture or dehiscence is managed with exploratory laparotomy, with either uterine repair or hysterectomy. Conservative surgery also requires completion of the pregnancy termination.</p><p class=\"headingAnchor\" id=\"H33\"><span class=\"h2\">Teratogenicity</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Questions regarding the teratogenicity of <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> may arise in cases where complete abortion is not achieved after one or more doses and a woman does not follow-up or chooses to continue a pregnancy. The teratogenic risk of misoprostol appears to be low and generally limited to first trimester exposure, according to a review of case reports [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/123\" class=\"abstract_t\">123</a>]. Despite the low risk, women who do not abort after induction with misoprostol should be counseled about the risk of fetal malformation with an ongoing pregnancy.</p><p>The mechanism for misoprostol-associated fetal malformations appears to be vascular disruption, possibly due to alteration of fetal blood flow due to uterine contractions [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/95,123-126\" class=\"abstract_t\">95,123-126</a>].</p><p class=\"headingAnchor\" id=\"H34\"><span class=\"h1\">MISOPROSTOL-ALONE COMPARED TO OTHER REGIMENS</span></p><p class=\"headingAnchor\" id=\"H35\"><span class=\"h2\">Misoprostol versus other prostaglandins</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Compared with other prostaglandins, <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> has less adverse effects, is orally active, temperature stable, less expensive, and widely available, including: PGE2 (<a href=\"topic.htm?path=dinoprostone-drug-information\" class=\"drug drug_general\">dinoprostone</a>) and PGF2alpha (carboprost) [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/127\" class=\"abstract_t\">127</a>].</p><p>In a systematic review of randomized trials in women undergoing pregnancy termination in the second or third trimester, vaginal <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> compared with gemeprost (another PGE1) was associated with reduced narcotic analgesia (RR 0.64, 95% CI 0.49-0.84) and surgical evacuation of the uterus (RR 0.71, 95% CI 0.53-0.95) [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/128\" class=\"abstract_t\">128</a>].</p><p class=\"headingAnchor\" id=\"H36\"><span class=\"h2\">Misoprostol versus mifepristone/misoprostol</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A combined regimen of <a href=\"topic.htm?path=mifepristone-drug-information\" class=\"drug drug_general\">mifepristone</a> and <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> is more effective than misoprostol-alone in a randomized trial [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/98\" class=\"abstract_t\">98</a>]; the misoprostol-only regimen would be of use in those settings where mifepristone is not available.</p><p>In addition, compared with combined therapy, women who administer misoprostol-alone may experience more fever and chills (probably due to higher and repeated doses), whereas women administered the combined therapy may experience more nausea and vomiting [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/111\" class=\"abstract_t\">111</a>]. Pretreatment with <a href=\"topic.htm?path=mifepristone-drug-information\" class=\"drug drug_general\">mifepristone</a> may also reduce the pain associated with the procedure.</p><p class=\"headingAnchor\" id=\"H37\"><span class=\"h2\">Misoprostol versus methotrexate/misoprostol</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Choice of misoprostol-alone and combined <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a><span class=\"nowrap\">/<a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a></span> is controversial [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/3\" class=\"abstract_t\">3</a>]. Data from randomized trials regarding the comparative efficacy of the two regimens are variable. Data from a large retrospective series reported that use of methotrexate with misoprostol was more effective than misoprostol-alone [<a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/2\" class=\"abstract_t\">2</a>]. However, methotrexate is not widely available and is more cumbersome to use than <a href=\"topic.htm?path=mifepristone-drug-information\" class=\"drug drug_general\">mifepristone</a> and misoprostol and misoprostol alone. Also, it can only be used safely through 7 weeks of gestation.</p><p class=\"headingAnchor\" id=\"H340901847\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-pregnancy-termination\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Pregnancy termination&quot;</a>.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword(s) of interest.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beyond the Basics topics (see <a href=\"topic.htm?path=abortion-pregnancy-termination-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Abortion (pregnancy termination) (Beyond the Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H39\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"headingAnchor\" id=\"H40\"><span class=\"h2\">Pretreatment considerations</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In women seeking pregnancy termination at nine or less weeks of gestation, we recommend <a href=\"topic.htm?path=mifepristone-drug-information\" class=\"drug drug_general\">mifepristone</a> with <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> versus misoprostol alone (<a href=\"grade.htm?i=1\" class=\"grade\">Grade 1A</a>). However, in settings where other medications are not accessible, use of misoprostol-alone for early pregnancy termination is an appropriate and effective choice. (See <a href=\"#H34\" class=\"local\">'Misoprostol-alone compared to other regimens'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">Misoprostol</a> is commonly used as a single agent for second trimester induced abortion in the United States and many other parts of the world. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In women undergoing pregnancy termination at 14 or more weeks, we recommend <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> over gemeprost (<a href=\"grade.htm?i=1\" class=\"grade\">Grade 1A</a>). (See <a href=\"#H35\" class=\"local\">'Misoprostol versus other prostaglandins'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In women undergoing second trimester pregnancy termination who are at high risk of uterine rupture (more than one hysterotomy, a prior classical or T-shaped uterine incision, or extensive transfundal uterine surgery [eg, myomectomy]), we suggest against using <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a>&nbsp;(<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). Misoprostol induction for pregnancy termination appears to be safe in women with one prior low transverse hysterotomy. Rupture is rarely associated with misoprostol use in first trimester. (See <a href=\"#H6\" class=\"local\">'Risk factors for uterine rupture'</a> above and <a href=\"topic.htm?path=choosing-the-route-of-delivery-after-cesarean-birth#H15065615\" class=\"medical medical_review\">&quot;Choosing the route of delivery after cesarean birth&quot;, section on 'Inappropriate candidates'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H41\"><span class=\"h2\">Clinical protocol</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In women undergoing pregnancy termination with misoprostol-alone, we suggest sublingual, rather than vaginal or oral, <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> dosing (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). Buccal dosing may be a reasonable alternative to sublingual. Sublingual and vaginal administration appear to be comparable in effectiveness and safety in randomized trials. Vaginal administration is more effective than oral, however, equivalent safety has not been confirmed. (See <a href=\"#H10\" class=\"local\">'Route of administration'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For women at 10 or fewer weeks, <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> can be administered at home or in a clinic setting. At 11 or more weeks, we conduct misoprostol treatment and monitoring in a clinic setting. (See <a href=\"#H13\" class=\"local\">'Clinical regimen'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The potency of the effect of <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a> varies with gestational age, as well as with route of administration, dose, dosing interval, and cumulative dose. Clinical protocols vary by gestational age (<a href=\"image.htm?imageKey=OBGYN%2F60845\" class=\"graphic graphic_table graphicRef60845 \">table 2</a>). (See <a href=\"#H9\" class=\"local\">'Data on drug administration'</a> above and <a href=\"#H13\" class=\"local\">'Clinical regimen'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Gastrointestinal symptoms (nausea, vomiting, diarrhea) and fever are the most common adverse effects of <a href=\"topic.htm?path=misoprostol-drug-information\" class=\"drug drug_general\">misoprostol</a>. These are generally transient and self-limiting. It is reasonable to give prophylactic anti-diarrheal medication to decrease the incidence of diarrhea; pretreatment does not appear to decrease other side effects. (See <a href=\"#H24\" class=\"local\">'Adverse effects'</a> above.)</p><p/><p class=\"headingAnchor\" id=\"H42\"><span class=\"h2\">Posttreatment issues</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Women should be educated about what is normal to expect following a medical abortion as well as how to recognize complications (eg, fever, abdominal pain, or prolonged or excessive bleeding) and how and when to seek help, if needed. (See <a href=\"#H22\" class=\"local\">'Follow-up'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Incomplete abortion or continuing pregnancy are the most common complications of medical abortion. This can be managed expectantly, medically, or surgically. (See <a href=\"#H28\" class=\"local\">'Complications'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Uterine rupture is a rare complication but should be suspected in a woman with severe or persistent abdominal pain and signs of intraabdominal bleeding. Prompt laparotomy is indicated in patients with a presumptive diagnosis of uterine rupture. (See <a href=\"#H28\" class=\"local\">'Complications'</a> above.)</p><p/><p class=\"headingAnchor\" id=\"H2428459676\"><span class=\"h1\">ACKNOWLEDGMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The editorial staff at UpToDate would like to acknowledge Wesley Clark, MD, MPH, who contributed to an earlier version of this topic review.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/1\" class=\"nounderline abstract_t\">Borgatta L, Mullally B, Vragovic O, et al. Misoprostol as the primary agent for medical abortion in a low-income urban setting. Contraception 2004; 70:121.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/2\" class=\"nounderline abstract_t\">Aldrich T, Winikoff B. Does methotrexate confer a significant advantage over misoprostol alone for early medical abortion? A retrospective analysis of 8678 abortions. BJOG 2007; 114:555.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/3\" class=\"nounderline abstract_t\">Wiebe ER, Trouton KJ, Lima R. Misoprostol alone vs. methotrexate followed by misoprostol for early abortion. Int J Gynaecol Obstet 2006; 95:286.</a></li><li class=\"breakAll\">United Nations Development Program/United Nations Fund for Population Activities/World Health Organization/World Bank Special Program of Research Development and Research Training in Human Reprod. Annual Technical Report, 1997. World Health Organization, Geneva, Switzerland 1998.</li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/5\" class=\"nounderline abstract_t\">Saha S, Bal R, Ghosh S, Krishnamurthy P. Medical abortion in late second trimester--a comparative study with misoprostol through vaginal versus oral followed by vaginal route. J Indian Med Assoc 2006; 104:81.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/6\" class=\"nounderline abstract_t\">Borgatta L, Kapp N, Society of Family Planning. Clinical guidelines. Labor induction abortion in the second trimester. Contraception 2011; 84:4.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/7\" class=\"nounderline abstract_t\">Tang J, Kapp N, Dragoman M, de Souza JP. WHO recommendations for misoprostol use for obstetric and gynecologic indications. Int J Gynaecol Obstet 2013; 121:186.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/8\" class=\"nounderline abstract_t\">American College of Obstetricians and Gynecologists. Practice bulletin no. 143: medical management of first-trimester abortion. Obstet Gynecol 2014; 123:676.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/9\" class=\"nounderline abstract_t\">Tang OS, Gemzell-Danielsson K, Ho PC. Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects. Int J Gynaecol Obstet 2007; 99 Suppl 2:S160.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/10\" class=\"nounderline abstract_t\">Zieman M, Fong SK, Benowitz NL, et al. Absorption kinetics of misoprostol with oral or vaginal administration. Obstet Gynecol 1997; 90:88.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/11\" class=\"nounderline abstract_t\">Tang OS, Schweer H, Seyberth HW, et al. Pharmacokinetics of different routes of administration of misoprostol. Hum Reprod 2002; 17:332.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/12\" class=\"nounderline abstract_t\">Danielsson KG, Marions L, Rodriguez A, et al. Comparison between oral and vaginal administration of misoprostol on uterine contractility. Obstet Gynecol 1999; 93:275.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/13\" class=\"nounderline abstract_t\">Arvidsson C, Hellborg M, Gemzell-Danielsson K. Preference and acceptability of oral versus vaginal administration of misoprostol in medical abortion with mifepristone. Eur J Obstet Gynecol Reprod Biol 2005; 123:87.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/14\" class=\"nounderline abstract_t\">Schaff EA, DiCenzo R, Fielding SL. Comparison of misoprostol plasma concentrations following buccal and sublingual administration. Contraception 2005; 71:22.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/15\" class=\"nounderline abstract_t\">Meckstroth KR, Whitaker AK, Bertisch S, et al. Misoprostol administered by epithelial routes: Drug absorption and uterine response. Obstet Gynecol 2006; 108:582.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/16\" class=\"nounderline abstract_t\">Creinin MD, Carbonell JL, Schwartz JL, et al. A randomized trial of the effect of moistening misoprostol before vaginal administration when used with methotrexate for abortion. Contraception 1999; 59:11.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/17\" class=\"nounderline abstract_t\">Sanchez-Ramos L, Danner CJ, Delke I, Kaunitz AM. The effect of tablet moistening on labor induction with intravaginal misoprostol: a randomized trial. Obstet Gynecol 2002; 99:1080.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/18\" class=\"nounderline abstract_t\">Bhattacharjee N, Saha SP, Ganguly RP, et al. A randomized comparative study on vaginal administration of acetic acid-moistened versus dry misoprostol for mid-trimester pregnancy termination. Arch Gynecol Obstet 2012; 285:311.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/19\" class=\"nounderline abstract_t\">Pongsatha S, Tongsong T. Randomized controlled study comparing misoprostol moistened with normal saline and with acetic acid for second-trimester pregnancy termination. Is it different? J Obstet Gynaecol Res 2011; 37:882.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/20\" class=\"nounderline abstract_t\">Lee VC, Yung SS, Li RH, et al. A randomized comparison of pharmacokinetics of a single vaginal dose of dry misoprostol or misoprostol moistened with normal saline or with acetic acid. Hum Reprod 2011; 26:2981.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/21\" class=\"nounderline abstract_t\">Goldberg AB, Greenberg MB, Darney PD. Misoprostol and pregnancy. N Engl J Med 2001; 344:38.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/22\" class=\"nounderline abstract_t\">Goyal V. Uterine rupture in second-trimester misoprostol-induced abortion after cesarean delivery: a systematic review. Obstet Gynecol 2009; 113:1117.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/23\" class=\"nounderline abstract_t\">Kim JO, Han JY, Choi JS, et al. Oral misoprostol and uterine rupture in the first trimester of pregnancy: a case report. Reprod Toxicol 2005; 20:575.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/24\" class=\"nounderline abstract_t\">Daskalakis GJ, Mesogitis SA, Papantoniou NE, et al. Misoprostol for second trimester pregnancy termination in women with prior caesarean section. BJOG 2005; 112:97.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/25\" class=\"nounderline abstract_t\">Dickinson JE. Misoprostol for second-trimester pregnancy termination in women with a prior cesarean delivery. Obstet Gynecol 2005; 105:352.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/26\" class=\"nounderline abstract_t\">El-Matary A, Navaratnarajah R, Economides DL. Ultrasound diagnosis of uterine dehiscence following mifepristone/misoprostol regime in early second trimester termination. J Obstet Gynaecol 2006; 26:578.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/27\" class=\"nounderline abstract_t\">Mazouni C, Provensal M, Porcu G, et al. Termination of pregnancy in patients with previous cesarean section. Contraception 2006; 73:244.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/28\" class=\"nounderline abstract_t\">Nayki U, Taner CE, Mizrak T, et al. Uterine rupture during second trimester abortion with misoprostol. Fetal Diagn Ther 2005; 20:469.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/29\" class=\"nounderline abstract_t\">Mazzone ME, Woolever J. Uterine rupture in a patient with an unscarred uterus: a case study. WMJ 2006; 105:64.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/30\" class=\"nounderline abstract_t\">Al-Hussaini TK. Uterine rupture in second trimester abortion in a grand multiparous woman. A complication of misoprostol and oxytocin. Eur J Obstet Gynecol Reprod Biol 2001; 96:218.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/31\" class=\"nounderline abstract_t\">Syed S, Noreen H, Kahloon LE, Chaudhri R. Uterine rupture associated with the use of intra-vaginal misoprostol during second-trimester pregnancy termination. J Pak Med Assoc 2011; 61:399.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/32\" class=\"nounderline abstract_t\">Cuellar Torriente M. Silent uterine rupture with the use of misoprostol for second trimester termination of pregnancy : a case report. Obstet Gynecol Int 2011; 2011:584652.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/33\" class=\"nounderline abstract_t\">Berghella V, Airoldi J, O'Neill AM, et al. Misoprostol for second trimester pregnancy termination in women with prior caesarean: a systematic review. BJOG 2009; 116:1151.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/34\" class=\"nounderline abstract_t\">Naguib AH, Morsi HM, Borg TF, et al. Vaginal misoprostol for second-trimester pregnancy termination after one previous cesarean delivery. Int J Gynaecol Obstet 2010; 108:48.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/35\" class=\"nounderline abstract_t\">Fawzy M, Abdel-Hady el-S. Midtrimester abortion using vaginal misoprostol for women with three or more prior cesarean deliveries. Int J Gynaecol Obstet 2010; 110:50.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/36\" class=\"nounderline abstract_t\">Andrikopoulou M, Lavery JA, Ananth CV, Vintzileos AM. Cervical ripening agents in the second trimester of pregnancy in women with a scarred uterus: a systematic review and metaanalysis of observational studies. Am J Obstet Gynecol 2016; 215:177.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/37\" class=\"nounderline abstract_t\">Lalitkumar S, Bygdeman M, Gemzell-Danielsson K. Mid-trimester induced abortion: a review. Hum Reprod Update 2007; 13:37.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/38\" class=\"nounderline abstract_t\">Ngai SW, Tang OS, Ho PC. Prostaglandins for induction of second-trimester termination and intrauterine death. Best Pract Res Clin Obstet Gynaecol 2003; 17:765.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/39\" class=\"nounderline abstract_t\">Vogel D, Burkhardt T, Rentsch K, et al. Misoprostol versus methylergometrine: pharmacokinetics in human milk. Am J Obstet Gynecol 2004; 191:2168.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/40\" class=\"nounderline abstract_t\">Jain JK, Mishell DR Jr. A comparison of misoprostol with and without laminaria tents for induction of second-trimester abortion. Am J Obstet Gynecol 1996; 175:173.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/41\" class=\"nounderline abstract_t\">Borgatta L, Chen AY, Vragovic O, et al. A randomized clinical trial of the addition of laminaria to misoprostol and hypertonic saline for second-trimester induction abortion. Contraception 2005; 72:358.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/42\" class=\"nounderline abstract_t\">Fjerstad M, Trussell J, Lichtenberg ES, et al. Severity of infection following the introduction of new infection control measures for medical abortion. Contraception 2011; 83:330.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/43\" class=\"nounderline abstract_t\">Fjerstad M, Trussell J, Sivin I, et al. Rates of serious infection after changes in regimens for medical abortion. N Engl J Med 2009; 361:145.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/44\" class=\"nounderline abstract_t\">Meites E, Zane S, Gould C, C. sordellii Investigators. Fatal Clostridium sordellii infections after medical abortions. N Engl J Med 2010; 363:1382.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/45\" class=\"nounderline abstract_t\">Chong E, Winikoff B, Charles D, et al. Vaginal and Rectal Clostridium sordellii and Clostridium perfringens Presence Among Women in the United States. Obstet Gynecol 2016; 127:360.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/46\" class=\"nounderline abstract_t\">Blanchard K, Shochet T, Coyaji K, et al. Misoprostol alone for early abortion: an evaluation of seven potential regimens. Contraception 2005; 72:91.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/47\" class=\"nounderline abstract_t\">Gilbert A, Reid R. A randomised trial of oral versus vaginal administration of misoprostol for the purpose of mid-trimester termination of pregnancy. Aust N Z J Obstet Gynaecol 2001; 41:407.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/48\" class=\"nounderline abstract_t\">Bebbington MW, Kent N, Lim K, et al. A randomized controlled trial comparing two protocols for the use of misoprostol in midtrimester pregnancy termination. Am J Obstet Gynecol 2002; 187:853.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/49\" class=\"nounderline abstract_t\">Dickinson JE, Evans SF. A comparison of oral misoprostol with vaginal misoprostol administration in second-trimester pregnancy termination for fetal abnormality. Obstet Gynecol 2003; 101:1294.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/50\" class=\"nounderline abstract_t\">Tang OS, Miao BY, Lee SW, Ho PC. Pilot study on the use of repeated doses of sublingual misoprostol in termination of pregnancy up to 12 weeks gestation: efficacy and acceptability. Hum Reprod 2002; 17:654.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/51\" class=\"nounderline abstract_t\">Cheung W, Tang OS, Lee SW, Ho PC. Pilot study on the use of sublingual misoprostol in termination of pregnancy up to 7 weeks gestation. Contraception 2003; 68:97.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/52\" class=\"nounderline abstract_t\">Bhattacharjee N, Saha SP, Ghoshroy SC, et al. A randomised comparative study on sublingual versus vaginal administration of misoprostol for termination of pregnancy between 13 to 20 weeks. Aust N Z J Obstet Gynaecol 2008; 48:165.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/53\" class=\"nounderline abstract_t\">Ngoc NT, Blum J, Raghavan S, et al. Comparing two early medical abortion regimens: mifepristone+misoprostol vs. misoprostol alone. Contraception 2011; 83:410.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/54\" class=\"nounderline abstract_t\">Ngoc NT, Shochet T, Raghavan S, et al. Mifepristone and misoprostol compared with misoprostol alone for second-trimester abortion: a randomized controlled trial. Obstet Gynecol 2011; 118:601.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/55\" class=\"nounderline abstract_t\">Salakos N, Kountouris A, Botsis D, et al. First-trimester pregnancy termination with 800 microg of vaginal misoprostol every 12 h. Eur J Contracept Reprod Health Care 2005; 10:249.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/56\" class=\"nounderline abstract_t\">Carbonell JL, Rodr&iacute;guez J, Velazco A, et al. Oral and vaginal misoprostol 800 microg every 8 h for early abortion. Contraception 2003; 67:457.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/57\" class=\"nounderline abstract_t\">Carbonell JL, Velazco A, Varela L, et al. Misoprostol for abortion at 9-12 weeks' gestation in adolescents. Eur J Contracept Reprod Health Care 2001; 6:39.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/58\" class=\"nounderline abstract_t\">Carbonell JL, Rodriguez J, Arag&oacute;n S, et al. Vaginal misoprostol 1000 microg for early abortion. Contraception 2001; 63:131.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/59\" class=\"nounderline abstract_t\">Velazco A, Varela L, Tanda R, et al. Misoprostol for abortion up to 9 weeks' gestation in adolescents. Eur J Contracept Reprod Health Care 2000; 5:227.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/60\" class=\"nounderline abstract_t\">Ngai SW, Tang OS, Chan YM, Ho PC. Vaginal misoprostol alone for medical abortion up to 9 weeks of gestation: efficacy and acceptability. Hum Reprod 2000; 15:1159.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/61\" class=\"nounderline abstract_t\">Esteve JL, Varela L, Velazco A, et al. Early abortion with 800 micrograms of misoprostol by the vaginal route. Contraception 1999; 59:219.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/62\" class=\"nounderline abstract_t\">Carbonell Esteve JL, Varela L, Velazco A, et al. Vaginal misoprostol for late first trimester abortion. Contraception 1998; 57:329.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/63\" class=\"nounderline abstract_t\">Carbonell JL, Varela L, Velazco A, et al. Vaginal misoprostol for abortion at 10-13 weeks' gestation. Eur J Contracept Reprod Health Care 1999; 4:35.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/64\" class=\"nounderline abstract_t\">Carbonell JL, Varela L, Velazco A, Fern&aacute;ndez C. The use of misoprostol for termination of early pregnancy. Contraception 1997; 55:165.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/65\" class=\"nounderline abstract_t\">Caliskan E, Dilbaz S, Doger E, et al. Randomized comparison of 3 misoprostol protocols for abortion induction at 13-20 weeks of gestation. J Reprod Med 2005; 50:173.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/66\" class=\"nounderline abstract_t\">Nakintu N. A comparative study of vaginal misoprostol and intravenous oxytocin for induction of labour in women with intra uterine fetal death in Mulago Hospital, Uganda. Afr Health Sci 2001; 1:55.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/67\" class=\"nounderline abstract_t\">von Hertzen H, Piaggio G, Huong NT, et al. Efficacy of two intervals and two routes of administration of misoprostol for termination of early pregnancy: a randomised controlled equivalence trial. Lancet 2007; 369:1938.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/68\" class=\"nounderline abstract_t\">Tang OS, Lau WN, Chan CC, Ho PC. A prospective randomised comparison of sublingual and vaginal misoprostol in second trimester termination of pregnancy. BJOG 2004; 111:1001.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/69\" class=\"nounderline abstract_t\">von Hertzen H, Piaggio G, Wojdyla D, et al. Comparison of vaginal and sublingual misoprostol for second trimester abortion: randomized controlled equivalence trial. Hum Reprod 2009; 24:106.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/70\" class=\"nounderline abstract_t\">Ganguly RP, Saha SP, Mukhopadhyay S, et al. A comparative study on sublingual versus oral and vaginal administration of misoprostol for late first and early second trimester abortion. J Indian Med Assoc 2010; 108:283.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/71\" class=\"nounderline abstract_t\">Cabrera Y, Fern&aacute;ndez-Guisasola J, Lobo P, et al. Comparison of sublingual versus vaginal misoprostol for second-trimester pregnancy termination: a meta-analysis. Aust N Z J Obstet Gynaecol 2011; 51:158.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/72\" class=\"nounderline abstract_t\">Wildschut H, Both MI, Medema S, et al. Medical methods for mid-trimester termination of pregnancy. Cochrane Database Syst Rev 2011; :CD005216.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/73\" class=\"nounderline abstract_t\">Blum J, Raghavan S, Dabash R, et al. Comparison of misoprostol-only and combined mifepristone-misoprostol regimens for home-based early medical abortion in Tunisia and Vietnam. Int J Gynaecol Obstet 2012; 118:166.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/74\" class=\"nounderline abstract_t\">Sayette H, Redwine D, Sivin I, et al.. Buccal use of misoprostol alone for early abortion: The experience in four Latin American countries (abstract). Contraception 2011; 84:302.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/75\" class=\"nounderline abstract_t\">Winikoff B, Dzuba IG, Creinin MD, et al. Two distinct oral routes of misoprostol in mifepristone medical abortion: a randomized controlled trial. Obstet Gynecol 2008; 112:1303.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/76\" class=\"nounderline abstract_t\">Middleton T, Schaff E, Fielding SL, et al. Randomized trial of mifepristone and buccal or vaginal misoprostol for abortion through 56 days of last menstrual period. Contraception 2005; 72:328.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/77\" class=\"nounderline abstract_t\">Kapp N, Borgatta L, Stubblefield P, et al. Mifepristone in second-trimester medical abortion: a randomized controlled trial. Obstet Gynecol 2007; 110:1304.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/78\" class=\"nounderline abstract_t\">Patel A, Talmont E, Morfesis J, et al. Adequacy and safety of buccal misoprostol for cervical preparation prior to termination of second-trimester pregnancy. Contraception 2006; 73:420.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/79\" class=\"nounderline abstract_t\">Ellis SC, Kapp N, Vragpvoc O, Borgata L. Randomized trial of buccal versus vaginal misoprostol for induction of second trimester abortion. Contraception 2010; 81:441.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/80\" class=\"nounderline abstract_t\">Liaquat NF, Javed I, Shuja S, et al. Therapeutic termination of second trimester pregnancies with low dose misoprostol. J Coll Physicians Surg Pak 2006; 16:464.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/81\" class=\"nounderline abstract_t\">Makhlouf AM, Al-Hussaini TK, Habib DM, Makarem MH. Second-trimester pregnancy termination: comparison of three different methods. J Obstet Gynaecol 2003; 23:407.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/82\" class=\"nounderline abstract_t\">Feldman DM, Borgida AF, Rodis JF, et al. A randomized comparison of two regimens of misoprostol for second-trimester pregnancy termination. Am J Obstet Gynecol 2003; 189:710.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/83\" class=\"nounderline abstract_t\">Fa&uacute;ndes A, Fiala C, Tang OS, Velasco A. Misoprostol for the termination of pregnancy up to 12 completed weeks of pregnancy. Int J Gynaecol Obstet 2007; 99 Suppl 2:S172.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/84\" class=\"nounderline abstract_t\">Guix C, Palacio M, Figueras F, et al. Efficacy of two regimens of misoprostol for early second-trimester pregnancy termination. Fetal Diagn Ther 2005; 20:544.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/85\" class=\"nounderline abstract_t\">Bugalho A, Fa&uacute;ndes A, Jamisse L, et al. Evaluation of the effectiveness of vaginal misoprostol to induce first trimester abortion. Contraception 1996; 53:244.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/86\" class=\"nounderline abstract_t\">Wong KS, Ngai CS, Yeo EL, et al. A comparison of two regimens of intravaginal misoprostol for termination of second trimester pregnancy: a randomized comparative trial. Hum Reprod 2000; 15:709.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/87\" class=\"nounderline abstract_t\">Herabutya Y, Chanrachakul B, Punyavachira P. A randomised controlled trial of 6 and 12 hourly administration of vaginal misoprostol for second trimester pregnancy termination. BJOG 2005; 112:1297.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/88\" class=\"nounderline abstract_t\">Dickinson JE, Evans SF. The optimization of intravaginal misoprostol dosing schedules in second-trimester pregnancy termination. Am J Obstet Gynecol 2002; 186:470.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/89\" class=\"nounderline abstract_t\">Edwards RK, Sims SM. Outcomes of second-trimester pregnancy terminations with misoprostol: comparing 2 regimens. Am J Obstet Gynecol 2005; 193:544.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/90\" class=\"nounderline abstract_t\">Dodd J, O'Brien L, Coffey J. Misoprostol for second and third trimester termination of pregnancy: a review of practice at the Women's and Children's Hospital, Adelaide, Australia. Aust N Z J Obstet Gynaecol 2005; 45:25.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/91\" class=\"nounderline abstract_t\">Langer BR, Peter C, Firtion C, et al. Second and third medical termination of pregnancy with misoprostol without mifepristone. Fetal Diagn Ther 2004; 19:266.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/92\" class=\"nounderline abstract_t\">Prachasilpchai N, Russameecharoen K, Borriboonhirunsarn D. Success rate of second-trimester termination of pregnancy using misoprostol. J Med Assoc Thai 2006; 89:1115.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/93\" class=\"nounderline abstract_t\">Perritt JB, Burke A, Edelman AB. Interruption of nonviable pregnancies of 24-28 weeks' gestation using medical methods: release date June 2013 SFP guideline #20133. Contraception 2013; 88:341.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/94\" class=\"nounderline abstract_t\">Bracken H, Ngoc NT, Banks E, et al. Buccal misoprostol for treatment of fetal death at 14-28 weeks of pregnancy: a double-blind randomized controlled trial. Contraception 2014; 89:187.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/95\" class=\"nounderline abstract_t\">Ho PC, Blumenthal PD, Gemzell-Danielsson K, et al. Misoprostol for the termination of pregnancy with a live fetus at 13 to 26 weeks. Int J Gynaecol Obstet 2007; 99 Suppl 2:S178.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/96\" class=\"nounderline abstract_t\">K&uuml;&ccedil;&uuml;kg&ouml;z G&uuml;le&ccedil; U, Urunsak IF, Eser E, et al. Misoprostol for midtrimester termination of pregnancy in women with 1 or more prior cesarean deliveries. Int J Gynaecol Obstet 2013; 120:85.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/97\" class=\"nounderline abstract_t\">Choudhary N, Bagga R, Raveendran A, et al. Second trimester abortion in women with and without previous uterine scar: Eleven years experience from a developing country. Eur J Contracept Reprod Health Care 2011; 16:378.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/98\" class=\"nounderline abstract_t\">Jain JK, Dutton C, Harwood B, et al. A prospective randomized, double-blinded, placebo-controlled trial comparing mifepristone and vaginal misoprostol to vaginal misoprostol alone for elective termination of early pregnancy. Hum Reprod 2002; 17:1477.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/99\" class=\"nounderline abstract_t\">Shaw D. Misoprostol for reproductive health: Dosage recommendations. Int J Gynaecol Obstet 2007; 99 Suppl 2:S155.</a></li><li class=\"breakAll\">Safe abortion: Technical and policy guidelines for health systems. World Health Organization, Geneva, 2003.</li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/101\" class=\"nounderline abstract_t\">Green J, Borgatta L, Sia M, et al. Intervention rates for placental removal following induction abortion with misoprostol. Contraception 2007; 76:310.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/102\" class=\"nounderline abstract_t\">Fiala C, Safar P, Bygdeman M, Gemzell-Danielsson K. Verifying the effectiveness of medical abortion; ultrasound versus hCG testing. Eur J Obstet Gynecol Reprod Biol 2003; 109:190.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/103\" class=\"nounderline abstract_t\">Harwood B, Meckstroth KR, Mishell DR, Jain JK. Serum beta-human chorionic gonadotropin levels and endometrial thickness after medical abortion. Contraception 2001; 63:255.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/104\" class=\"nounderline abstract_t\">Luise C, Jermy K, Collons WP, Bourne TH. Expectant management of incomplete, spontaneous first-trimester miscarriage: outcome according to initial ultrasound criteria and value of follow-up visits. Ultrasound Obstet Gynecol 2002; 19:580.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/105\" class=\"nounderline abstract_t\">Creinin MD, Harwood B, Guido RS, et al. Endometrial thickness after misoprostol use for early pregnancy failure. Int J Gynaecol Obstet 2004; 86:22.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/106\" class=\"nounderline abstract_t\">Reynolds A, Ayres-de-Campos D, Costa MA, Montenegro N. How should success be defined when attempting medical resolution of first-trimester missed abortion? Eur J Obstet Gynecol Reprod Biol 2005; 118:71.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/107\" class=\"nounderline abstract_t\">Reeves MF, Fox MC, Lohr PA, Creinin MD. Endometrial thickness following medical abortion is not predictive of subsequent surgical intervention. Ultrasound Obstet Gynecol 2009; 34:104.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/108\" class=\"nounderline abstract_t\">Lynd K, Blum J, Ngoc NT, et al. Simplified medical abortion using a semi-quantitative pregnancy test for home-based follow-up. Int J Gynaecol Obstet 2013; 121:144.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/109\" class=\"nounderline abstract_t\">Blum J, Shochet T, Lynd K, et al. Can at-home semi-quantitative pregnancy tests serve as a replacement for clinical follow-up of medical abortion? A US study. Contraception 2012; 86:757.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/110\" class=\"nounderline abstract_t\">Honkanen H, Piaggio G, Hertzen H, et al. WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. BJOG 2004; 111:715.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/111\" class=\"nounderline abstract_t\">Ngai SW, Tang OS, Ho PC. Randomized comparison of vaginal (200 microg every 3 h) and oral (400 microg every 3 h) misoprostol when combined with mifepristone in termination of second trimester pregnancy. Hum Reprod 2000; 15:2205.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/112\" class=\"nounderline abstract_t\">Baird DT. Medical abortion in the first trimester. Best Pract Res Clin Obstet Gynaecol 2002; 16:221.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/113\" class=\"nounderline abstract_t\">Durocher J, Bynum J, Le&oacute;n W, et al. High fever following postpartum administration of sublingual misoprostol. BJOG 2010; 117:845.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/114\" class=\"nounderline abstract_t\">Philip NM, Winikoff B, Moore K, Blumenthal P. A consensus regimen for early abortion with misoprostol. Int J Gynaecol Obstet 2004; 87:281.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/115\" class=\"nounderline abstract_t\">Shannon C, Brothers LP, Philip NM, Winikoff B. Infection after medical abortion: a review of the literature. Contraception 2004; 70:183.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/116\" class=\"nounderline abstract_t\">Fischer M, Bhatnagar J, Guarner J, et al. Fatal toxic shock syndrome associated with Clostridium sordellii after medical abortion. N Engl J Med 2005; 353:2352.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/117\" class=\"nounderline abstract_t\">Sinave C, Le Templier G, Blouin D, et al. Toxic shock syndrome due to Clostridium sordellii: a dramatic postpartum and postabortion disease. Clin Infect Dis 2002; 35:1441.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/118\" class=\"nounderline abstract_t\">Couzin J. infectious disease. RU-486-linked deaths open debate about risky bacteria. Science 2006; 312:986.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/119\" class=\"nounderline abstract_t\">Winikoff B. Clostridium sordellii infection in medical abortion. Clin Infect Dis 2006; 43:1447.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/120\" class=\"nounderline abstract_t\">Aronoff DM, Hao Y, Chung J, et al. Misoprostol impairs female reproductive tract innate immunity against Clostridium sordellii. J Immunol 2008; 180:8222.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/121\" class=\"nounderline abstract_t\">Jain JK, Harwood B, Meckstroth KR, Mishell DR. Early pregnancy termination with vaginal misoprostol combined with loperamide and acetaminophen prophylaxis. Contraception 2001; 63:217.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/122\" class=\"nounderline abstract_t\">Daskalakis G, Papantoniou N, Mesogitis S, et al. Sonographic findings and surgical management of a uterine rupture associated with the use of misoprostol during second-trimester abortion. J Ultrasound Med 2005; 24:1565.</a></li><li class=\"breakAll\">Misoprostol and teratology: Reviewing the evidence, Philip, N, Shannon, C, Winikoff, B (Eds), Population Council, New York 2002.</li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/124\" class=\"nounderline abstract_t\">Orioli IM, Castilla EE. Epidemiological assessment of misoprostol teratogenicity. BJOG 2000; 107:519.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/125\" class=\"nounderline abstract_t\">Castilla EE, Orioli IM. Teratogenicity of misoprostol: data from the Latin-American Collaborative Study of Congenital Malformations (ECLAMC). Am J Med Genet 1994; 51:161.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/126\" class=\"nounderline abstract_t\">Addar MH. Methotrexate embryopathy in a surviving intrauterine fetus after presumed diagnosis of ectopic pregnancy: case report. J Obstet Gynaecol Can 2004; 26:1001.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/127\" class=\"nounderline abstract_t\">Csapo AI. The prospects of PGs in postconceptional therapy. Prostaglandins 1973; 3:245.</a></li><li><a href=\"https://www.uptodate.com/contents/misoprostol-as-a-single-agent-for-medical-termination-of-pregnancy/abstract/128\" class=\"nounderline abstract_t\">Dodd JM, Crowther CA. Misoprostol versus cervagem for the induction of labour to terminate pregnancy in the second and third trimester: a systematic review. Eur J Obstet Gynecol Reprod Biol 2006; 125:3.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 5434 Version 14.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H39\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">PHARMACOKINETICS</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">CONTRAINDICATIONS</a><ul><li><a href=\"#H4\" id=\"outline-link-H4\">Absolute contraindications</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Relative contraindications</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Risk factors for uterine rupture</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">Breastfeeding</a></li></ul></li><li><a href=\"#H8\" id=\"outline-link-H8\">PRETREATMENT EVALUATION AND PREPARATION</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">DATA ON DRUG ADMINISTRATION</a><ul><li><a href=\"#H10\" id=\"outline-link-H10\">Route of administration</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">Dose and dosing interval</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">Number of doses</a></li></ul></li><li><a href=\"#H13\" id=\"outline-link-H13\">CLINICAL REGIMEN</a><ul><li><a href=\"#H14\" id=\"outline-link-H14\">9 or less weeks</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">10 to 12 weeks</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">13 to 22 weeks</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">23 or more weeks</a></li></ul></li><li><a href=\"#H18\" id=\"outline-link-H18\">MONITORING DURING TREATMENT</a><ul><li><a href=\"#H19\" id=\"outline-link-H19\">At-home treatment</a></li><li><a href=\"#H20\" id=\"outline-link-H20\">Facility-based treatment</a></li></ul></li><li><a href=\"#H22\" id=\"outline-link-H22\">FOLLOW-UP</a></li><li><a href=\"#H23\" id=\"outline-link-H23\">OUTCOME</a></li><li><a href=\"#H24\" id=\"outline-link-H24\">ADVERSE EFFECTS</a><ul><li><a href=\"#H25\" id=\"outline-link-H25\">Gastrointestinal symptoms</a></li><li><a href=\"#H26\" id=\"outline-link-H26\">Fever</a></li><li><a href=\"#H27\" id=\"outline-link-H27\">Prevention of adverse effects</a></li></ul></li><li><a href=\"#H28\" id=\"outline-link-H28\">COMPLICATIONS</a><ul><li><a href=\"#H29\" id=\"outline-link-H29\">Incomplete abortion</a><ul><li><a href=\"#H30\" id=\"outline-link-H30\">- First trimester</a></li><li><a href=\"#H31\" id=\"outline-link-H31\">- Second trimester</a></li></ul></li><li><a href=\"#H32\" id=\"outline-link-H32\">Uterine rupture</a></li><li><a href=\"#H33\" id=\"outline-link-H33\">Teratogenicity</a></li></ul></li><li><a href=\"#H34\" id=\"outline-link-H34\">MISOPROSTOL-ALONE COMPARED TO OTHER REGIMENS</a><ul><li><a href=\"#H35\" id=\"outline-link-H35\">Misoprostol versus other prostaglandins</a></li><li><a href=\"#H36\" id=\"outline-link-H36\">Misoprostol versus mifepristone/misoprostol</a></li><li><a href=\"#H37\" id=\"outline-link-H37\">Misoprostol versus methotrexate/misoprostol</a></li></ul></li><li><a href=\"#H340901847\" id=\"outline-link-H340901847\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H38\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H39\" id=\"outline-link-H39\">SUMMARY AND RECOMMENDATIONS</a><ul><li><a href=\"#H40\" id=\"outline-link-H40\">Pretreatment considerations</a></li><li><a href=\"#H41\" id=\"outline-link-H41\">Clinical protocol</a></li><li><a href=\"#H42\" id=\"outline-link-H42\">Posttreatment issues</a></li></ul></li><li><a href=\"#H2428459676\" id=\"outline-link-H2428459676\">ACKNOWLEDGMENT</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"OBGYN/5434|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=OBGYN/58285\" class=\"graphic graphic_table\">- Misoprostol abortion rupture</a></li><li><a href=\"image.htm?imageKey=OBGYN/60845\" class=\"graphic graphic_table\">- Misoprostol-only protocol</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=choosing-the-route-of-delivery-after-cesarean-birth\" class=\"medical medical_review\">Choosing the route of delivery after cesarean birth</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=fetal-death-and-stillbirth-incidence-etiology-and-prevention\" class=\"medical medical_review\">Fetal death and stillbirth: Incidence, etiology, and prevention</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=first-trimester-medication-abortion-termination-of-pregnancy\" class=\"medical medical_review\">First-trimester medication abortion (termination of pregnancy)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=first-trimester-pregnancy-termination-uterine-aspiration\" class=\"medical medical_review\">First-trimester pregnancy termination: Uterine aspiration</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-pregnancy-termination\" class=\"medical medical_review\">Overview of pregnancy termination</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-second-trimester-pregnancy-termination\" class=\"medical medical_review\">Overview of second-trimester pregnancy termination</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=abortion-pregnancy-termination-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Abortion (pregnancy termination) (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prevention-of-rhesus-d-alloimmunization-in-pregnancy\" class=\"medical medical_review\">Prevention of Rhesus (D) alloimmunization in pregnancy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=second-trimester-pregnancy-termination-induction-medication-termination\" class=\"medical medical_review\">Second-trimester pregnancy termination: Induction (medication) termination</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-pregnancy-termination\" class=\"medical medical_society_guidelines\">Society guideline links: Pregnancy termination</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=spontaneous-abortion-management\" class=\"medical medical_review\">Spontaneous abortion: Management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=techniques-for-ripening-the-unfavorable-cervix-prior-to-induction\" class=\"medical medical_review\">Techniques for ripening the unfavorable cervix prior to induction</a></li></ul></div></div>","javascript":null}